Simrat Randhawa Sells 26,530 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Simrat Randhawa also recently made the following trade(s):

• On Thursday, March 12th, Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40.

Dianthus Therapeutics Price Performance

NASDAQ DNTH traded down $7.88 during mid-day trading on Tuesday, hitting $81.57. The stock had a trading volume of 1,057,924 shares, compared to its average volume of 877,083. The firm’s 50 day moving average is $86.99 and its 200 day moving average is $62.62. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of -19.75 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Fairmount Funds Management LLC raised its holdings in shares of Dianthus Therapeutics by 22.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after acquiring an additional 600,000 shares during the period. Vestal Point Capital LP raised its holdings in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the period. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC raised its holdings in shares of Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DNTH shares. Wedbush increased their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Robert W. Baird increased their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Wells Fargo & Company started coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Finally, Truist Financial increased their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and a consensus target price of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.